Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclic versus continuous medroxyprogesterone acetate for endometrial hyperplasia without atypia
PACTR201508001237608Unknown
- Sponsor
- Faculty of Medicine
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of medroxyprogesterone acetate in Endometrial Hyperplasia Without Atypia (EH) (2 arms), sponsored by Faculty of Medicine. Primary endpoint: Regression of hyperplasia after 6 months of progestin therapy. Status: unknown.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Endometrial Hyperplasia Without Atypia (EH)
Beyond the preview
Go deeper on PACTR201508001237608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201508001237608.